Skip to Main Content

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)

Conditions

Diseases of the Digestive System - Liver

Phase II

What is the purpose of this trial?

This research study is for people who may have abnormally high amount of fat and swelling (inflammation) of their liver along with some fibrosis (scarring) that is not related to excessive alcohol consumption. The medical term for this condition is nonalcoholic steatohepatitis (NASH) that has both high liver fat and inflammation (swelling) and fibrosis (scarring) that causes a stiff liver. This research study involves two investigational drugs (study drugs) as potential options to treat patients with NASH with liver fibrosis.

  • Trial with
    Pfizer Inc., U.S. Pharmaceuticals Group
  • Start Date
    01/08/2021
  • End Date
    11/01/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/26/2021
  • Study HIC
    #2000027577